Mobocertinib added in NICE guidelines
NICE guidelines have added the guidance on mobocertinib to the systemic anti-cancer therapy treatment pathways for advanced non-small-cell lung cancer.
They would like your feedback on how the treatment pathways present content from different sources (NICE technology appraisal guidance, guideline recommendations, and expert input). To comment, go to the link below on systemic anti-cancer therapy for advanced non-small-cell lung cancer and fill in the pop-up survey.
Recent Posts
EU Medicines Regulation Achievements: EMA’s 2025 Highlights and Future Directions
The European Medicines Agency (EMA) Management Board highlights at its March 2026 meeting a robust year, with the adoption of the 2025 annual report detailing 104 positive recommendations for new hu...
Quantifying Cancer Productivity Losses in Europe: Economic Impact Analysis
Cancer productivity losses from premature mortality and morbidity due to leading cancers across 28 European countries in 2022 totaled €39.8 billion, as estimated via the human capital approach in this study....
Biomarin Withdraws Voxzogo Reimbursement Application in the Netherlands
Voxzogo reimbursement Netherlands hangs in limbo after Biomarin's decision on March 12, 2026, to withdraw its application, leaving children with achondroplasia without access despite parental pleas.